Genomic diagnostics firm Veracyte Q3 revenue beats estimates on higher testings

Veracyte

04/11/2025 21:14

Overview

Veracyte Q3 2025 revenue grows 14% yr/yr, beating analyst expectations

Testing revenue increased 17% yr/yr, driven by Decipher and Afirma tests

Company raises full-year revenue and profitability guidance

Outlook

Veracyte raises 2025 testing revenue guidance to $484 mln-$487 mln

Company raises 2025 total revenue guidance to $506 mln-$510 mln

Veracyte increases 2025 adjusted EBITDA guidance to over 25% of revenue

Result Drivers

TESTING REVENUE GROWTH - Driven by 17% increase in testing revenue, led by Decipher and Afirma tests

PRODUCT LAUNCHES - Upcoming launches of TrueMRD and Prosigna LDT expected to support long-term growth

CLINICAL TRIALS - Presentation of Decipher-focused abstracts and completion of NIGHTINGALE trial enhance market leadership

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$131.90 mln
$124.60 mln (9 Analysts)
Q3 Net Income
$19.10 mln
Q3 Gross Margin
69%
Q3 Adjusted Operating Expenses
$58.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Veracyte Inc is $42.00, about 13.2% above its November 3 closing price of $36.45

The stock recently traded at 49 times the next 12-month earnings vs. a P/E of 38 three months ago

Press Release: ID:nBw5JHRd3a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)